Aliases & Classifications for Urticaria

MalaCards integrated aliases for Urticaria:

Name: Urticaria 12 77 30 56 6 45 15 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:1555
ICD9CM 36 708.8
MeSH 45 D014581
ICD10 34 L50

Summaries for Urticaria

Disease Ontology : 12 A skin disease characterized by skin rash notable for pale red, raised and itchy bumps, located in the upper dermis.

MalaCards based summary : Urticaria is related to physical urticaria and cold urticaria, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Urticaria is F12 (Coagulation Factor XII), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and NF-kappaB Signaling. The drugs Clarinex and Histamine have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and thyroid, and related phenotypes are hematopoietic system and immune system

Wikipedia : 77 Hives, also known as urticaria, is a kind of skin rash with red, raised, itchy bumps. They may also burn... more...

Related Diseases for Urticaria

Diseases related to Urticaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 404)
# Related Disease Score Top Affiliating Genes
1 physical urticaria 34.2 ADGRE2 FCER1A
2 cold urticaria 34.2 CMA1 NLRP3 PLCG2 RNASE3
3 angioedema 31.0 C1S CPN1 F12 HNMT LTC4S PTGS1
4 rhinitis 30.8 HRH1 IGHE RNASE3
5 allergic rhinitis 30.5 HRH1 IGHE RNASE3
6 toxocariasis 30.2 IGHE RNASE3
7 latex allergy 30.0 IGHE RNASE3
8 allergic hypersensitivity disease 29.8 FCER2 HRH1 IGHE RNASE3 TPT1
9 conjunctivitis 29.7 HRH1 NLRP3 RNASE3
10 dermatitis, atopic 29.6 CMA1 FCER2 HRH1 IGHE RNASE3 SELE
11 asthma 28.6 FCER1A FCER2 HNMT HRH1 IGHE LTC4S
12 vibratory urticaria 12.7
13 cholinergic urticaria 12.6
14 solar urticaria 12.6
15 allergic urticaria 12.6
16 urticaria, aquagenic 12.5
17 papular urticaria 12.4
18 familial cold autoinflammatory syndrome 3 12.2
19 schnitzler syndrome 12.2
20 mastocytosis, cutaneous 12.2
21 familial cold autoinflammatory syndrome 1 12.2
22 muckle-wells syndrome 12.2
23 nodular urticaria pigmentosa 12.1
24 dermatographia 12.1
25 urticaria, familial localized heat 12.0
26 plaque-form urticaria pigmentosa 12.0
27 typical urticaria pigmentosa 12.0
28 familial cold autoinflammatory syndrome 11.9
29 dermographism, familial 11.7
30 familial cold autoinflammatory syndrome 4 11.3
31 exercise-induced anaphylaxis 11.3
32 cryopyrin-associated periodic syndrome 11.3
33 fascioliasis 11.1
34 hypersensitivity vasculitis 11.1
35 arthus reaction 11.0
36 carboxypeptidase n deficiency 11.0
37 netherton syndrome 11.0
38 familial cold autoinflammatory syndrome 2 11.0
39 deafness, autosomal dominant 34, with or without inflammation 11.0
40 paragonimiasis 11.0
41 cystic echinococcosis 11.0
42 anca-associated vasculitis 11.0
43 cutaneous mastocytoma 11.0
44 distomatosis 11.0
45 episodic angioedema with eosinophilia 11.0
46 hypocomplementemic urticarial vasculitis 11.0
47 monoclonal mast cell activation syndrome 11.0
48 erythema multiforme 10.6
49 dermatitis 10.6
50 mastocytosis 10.5

Comorbidity relations with Urticaria via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential
Ischemic Heart Disease

Graphical network of the top 20 diseases related to Urticaria:



Diseases related to Urticaria

Symptoms & Phenotypes for Urticaria

UMLS symptoms related to Urticaria:


nausea and vomiting, constipation, fever, fatigue, abdominal pain, edema, pruritus, pain, headache, chest pain, diarrhea, syncope, chronic pain, sciatica, icterus, exanthema, coughing, vertigo/dizziness, dyspepsia, heartburn, gastrointestinal gas, symptoms, halitosis, pelvic pain, welts, darier's sign

MGI Mouse Phenotypes related to Urticaria:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.61 CMA1 FCER1A FCER2 HRH1 NLRP3 PLCG2
2 immune system MP:0005387 9.36 CMA1 CPN1 FCER1A FCER2 HRH1 LTC4S

Drugs & Therapeutics for Urticaria

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Clarinex 19 DESLORATADINE Schering-Plough February 2002

Drugs for Urticaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 464)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6 774
2
Desloratadine Approved, Investigational Phase 4,Phase 3,Phase 2 100643-71-8 124087
3
Levocetirizine Approved Phase 4,Phase 3,Phase 1,Phase 2 130018-77-8 1549000
4
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83881-51-0 2678
5
Dapsone Approved, Investigational Phase 4 80-08-0 2955
6
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 143 6006
7
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
8
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 242138-07-4
9
Hydroxyzine Approved Phase 4 68-88-2 3658
10
Fexofenadine Approved, Investigational Phase 4,Phase 2 83799-24-0 3348
11
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
12
Loratadine Approved, Investigational Phase 4,Phase 3,Phase 2 79794-75-5 3957
13
Cefazolin Approved Phase 4,Not Applicable 25953-19-9 33255 656510
14
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
15
Clevidipine Approved, Investigational Phase 4 167221-71-8
16
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 22916-47-8 4189
18
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
19
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
20
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
21
Azelastine Approved Phase 4,Phase 3 58581-89-8 2267
22
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
23
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
24
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
25
Icatibant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130308-48-4, 138614-30-9 71364
26
Zinc Approved, Investigational Phase 4 7440-66-6 32051
27
Tranexamic Acid Approved Phase 4,Phase 3 1197-18-8 5526
28 Benralizumab Approved, Investigational Phase 4 1044511-01-4
29
Menthol Approved Phase 4 2216-51-5 16666
30
Tofacitinib Approved, Investigational Phase 4 477600-75-2
31
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
33
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Not Applicable 7440-70-2 271
34
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 50-14-6 5280793
35
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 1406-16-2
36
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
37
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
38
Bradykinin Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-82-2 439201
39
Lactitol Investigational Phase 4,Phase 2 585-88-6, 585-86-4 493591
40 Histamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Cholinergic Antagonists Phase 4,Phase 3,Phase 2
45
Histamine Phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-74-1 65513
46 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 3,Phase 2
48 Antimalarials Phase 4,Not Applicable
49 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
50 Vitamin B9 Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 551)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria Unknown status NCT00346606 Phase 4 Denosin® and Xyzal®
2 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
3 Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery Unknown status NCT02672813 Phase 4
4 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed NCT02550106 Phase 4 OMALIZUMAB
5 Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses Completed NCT01250652 Phase 4 Levocetirizine;Levocetirizine plus Hydroxyzine
6 Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria Completed NCT01940393 Phase 4 Cetirizine;Desloratadine;Fexofenadine;Ebastine;Bilastine
7 A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria Completed NCT02392624 Phase 4 Omalizumab;Placebo
8 Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria Completed NCT01444196 Phase 4 Desloratadine
9 A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions Completed NCT00600847 Phase 4 desloratadine;desloratadine;placebo
10 Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria Completed NCT01701583 Phase 4 Omalizumab
11 Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849) Completed NCT00536380 Phase 4 5-mg Desloratadine;10-mg Desloratadine;20-mg Desloratadine
12 CUTE (Chronic Urticaria Treatment Evaluation) Completed NCT00264303 Phase 4 Levocetirizine;Desloratadine
13 A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147) Completed NCT00783354 Phase 4 desloratadine;desloratadine
14 An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540) Completed NCT00795522 Phase 4 Desloratadine
15 A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735) Completed NCT00751218 Phase 4 desloratadine;placebo;cetirizine
16 Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Completed NCT02576041 Phase 4 Bilastine;Placebo
17 Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Completed NCT01244698 Phase 4 Cefadroxil discontinued early;Cefadroxil until drain removal
18 Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed Completed NCT01121458 Phase 4 Clevidipine
19 Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China Completed NCT02336178 Phase 4 Benefix
20 Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Completed NCT01567865 Phase 4
21 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
22 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma Completed NCT00267202 Phase 4 Placebo;Omalizumab;Immunotherapy;Immunotherapy
23 The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients) Completed NCT00777764 Phase 4 Cohort I;Cohort 2
24 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
25 Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease Completed NCT00549601 Phase 4 Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day);Rivastigmine patch (9.5 mg/day);Rivastigmine capsules (6 mg to 12 mg/day)
26 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
27 Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR Completed NCT01880840 Phase 4 205.5 mcg of azelastine hydrochloride;137 mcg of azelastine hydrochloride
28 Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women Completed NCT01937234 Phase 4 Metoclopramide;Placebo
29 RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Operative Vaginal Reconstruction Pain Completed NCT02043704 Phase 4 IV Acetaminophen
30 A Call Center During HAE Attacks (SOS HAE) Completed NCT01679912 Phase 4
31 Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Completed NCT01467947 Phase 4
32 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed NCT01457430 Phase 4 Icatibant
33 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE Completed NCT00914966 Phase 4
34 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
35 Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety Completed NCT00359801 Phase 4 Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care;Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
36 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) Recruiting NCT03111628 Phase 4 Omalizumab
37 Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody Recruiting NCT03183024 Phase 4
38 Menthol for PDT Pain Relief Recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
39 Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients Recruiting NCT03016884 Phase 4
40 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Recruiting NCT02966314 Phase 4 Omalizumab;Placebos
41 Safety of Rabivax-S for Pre-exposure Prophylaxis Enrolling by invitation NCT03741270 Phase 4
42 Tranexamic Acid and Spontaneous Chronic Urticaria Not yet recruiting NCT03789422 Phase 4 association of levocetirizine and tranexamic acid;Levocetirizine only
43 Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery Not yet recruiting NCT03460509 Phase 4 Sugammadex
44 A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736) Terminated NCT00751166 Phase 4 Desloratadine;Cetirizine;placebo
45 A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
46 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema Terminated NCT01574248 Phase 4 icatibant
47 Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation Withdrawn NCT02742805 Phase 4 Omalizumab
48 Ceftaroline in the Treatment of Bone and Joint Infections Withdrawn NCT02005068 Phase 4 Ceftaroline
49 C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation Withdrawn NCT01151735 Phase 4 C-1-esterase;C-1-esterase;placebo
50 High Dose Vitamin D Supplementation in Chronic Spontaneous Urticaria Unknown status NCT02873364 Phase 3 Vitamin D3 (High dose);Vitamin D3 (Low dose)

Search NIH Clinical Center for Urticaria

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: urticaria

Genetic Tests for Urticaria

Genetic tests related to Urticaria:

# Genetic test Affiliating Genes
1 Urticaria 30

Anatomical Context for Urticaria

MalaCards organs/tissues related to Urticaria:

42
Skin, Testes, Thyroid, T Cells, Neutrophil, Brain, Myeloid

The Foundational Model of Anatomy Ontology organs/tissues related to Urticaria:

20
The Upper Dermis

Publications for Urticaria

Articles related to Urticaria:

(show top 50) (show all 4092)
# Title Authors Year
1
Chronic spontaneous urticaria associated with colon adenocarcinoma: A paraneoplastic manifestation? A case report and review of literature. ( 30581946 )
2019
2
Ebastine in the treatment of allergic rhinitis and urticaria: 30 years of clinical studies and real-world experience. ( 30977465 )
2019
3
Chronic urticaria revealing amebiasis. ( 29908957 )
2019
4
Trends in hospitalizations related to anaphylaxis, angioedema and urticaria in the United States. ( 30769181 )
2019
5
Does angioedema influence the quality of life in chronic spontaneous urticaria patients? ( 30769182 )
2019
6
Chronic spontaneous urticaria and angioedema requiring treatment with omalizumab in a patient with hereditary angioedema. ( 30831259 )
2019
7
Cost-utility of routine testing in chronic urticaria/angioedema: A cohort study. ( 31054327 )
2019
8
Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study. ( 30238582 )
2019
9
Angioedema frequently occurs in cholinergic urticaria. ( 30368007 )
2019
10
Epidemiology of urticaria including physical urticaria and angioedema in Korea. ( 29742892 )
2019
11
Higher Levels of Depression and Anxiety in Patients with Chronic Urticaria. ( 30609422 )
2019
12
Occupational rhinitis, asthma, and contact urticaria from IgE-mediated allergy to pork. ( 30474282 )
2019
13
Real-life treatment of cholinergic urticaria with omalizumab. ( 30312709 )
2019
14
Efficacy and safety of omalizumab (Xolair®) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial. ( 30654196 )
2019
15
Exercise-induce anaphylaxis, food-dependent exercise-induce anaphylaxis, cholinergic urticaria and Kounis syndrome. ( 30774109 )
2019
16
JAAD Game Changers: Acquired cold urticaria: Clinical features, particular phenotypes, and disease course in a tertiary care center cohort. ( 30447322 )
2019
17
H1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria. ( 30708143 )
2019
18
Treatments of Cold Urticaria: A Systematic Review. ( 30776418 )
2019
19
Contact dermatitis with concomitant contact urticaria syndrome due to multiple ingredients of oxidative hair dye. ( 29866587 )
2019
20
Food-Related Contact Dermatitis, Contact Urticaria, and Atopy Patch Test with Food. ( 29881951 )
2019
21
Omalizumab in An 8-Year-Old Boy With Diabetes Mellitus and Refractory Chronic Spontaneous Urticaria. ( 31017115 )
2019
22
Cold-induced urticaria in a child with familial Mediterranean fever. ( 30961846 )
2019
23
Headache deteriorates the quality of life in children with chronic spontaneous urticaria. ( 30686612 )
2019
24
Impact of chronic urticaria on systemic lupus erythematosus: A nationwide population-based study in Taiwan. ( 30368876 )
2019
25
Oral suplatast tosilate for the treatment of urticaria pigmentosa, skin lesion in mastocytosis. ( 30456758 )
2019
26
Common food flavors are safe in patients with urticaria or atopic dermatitis. ( 30006048 )
2019
27
The Prevalence of Atopic Dermatitis and Chronic Spontaneous Urticaria are Associated with Parental Socioeconomic Status in Adolescents in China. ( 30521061 )
2019
28
Cellular and Humoral Responses to Cte f 2, a Cat Flea Allergen, in Children with Papular Urticaria. ( 30904917 )
2019
29
Urticaria pigmentosa-like skin disease in a domestic shorthair cat. ( 30671254 )
2019
30
Polymorphous light eruption with complication of solar urticaria revealed by phototesting. ( 30302798 )
2019
31
Evaluating patient responses to omalizumab in solar urticaria. ( 30338865 )
2019
32
Evaluation of nine patients with solar urticaria during summer. ( 30924623 )
2019
33
Real-life experience in the treatment of solar urticaria: retrospective cohort study. ( 30828851 )
2019
34
Patient experiences of using Chinese herbal medicine for psoriasis vulgaris and chronic urticaria: A qualitative study. ( 30897010 )
2019
35
Serum galectin-1, galectin-3 and galectin-9 are bystander molecules for chronic spontaneous urticaria. ( 31006131 )
2019
36
Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria. ( 31025425 )
2019
37
Chronic urticaria - bad to the bone? ( 31025726 )
2019
38
Contact urticaria following the use of a cosmetic containing caprylyl glycol: A case report. ( 31026059 )
2019
39
The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria. ( 31030540 )
2019
40
Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU). ( 31034999 )
2019
41
Refractory urticaria and the importance of diagnosing Schnitzler's syndrome. ( 31036740 )
2019
42
Fifteen-minute consultation: Assessing the child with persistent urticaria. ( 31048341 )
2019
43
Combined differentiated therapy in patients with urticaria. ( 31055538 )
2019
44
Omalizumab for Chronic Urticaria in Children Less than 12 Years of Age: A Systematic Review. ( 31082483 )
2019
45
Long-term effects of omalizumab on peripheral blood cells and C-reactive protein levels in patients with chronic spontaneous urticaria. ( 31087491 )
2019
46
Systematic reviews of pharmacological and nonpharmacological treatments for patients with chronic urticaria: An umbrella systematic review. ( 31096521 )
2019
47
A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: A real-world study in Belgium. ( 31099916 )
2019
48
ASSOCIATION BETWEEN URTICARIA AND INFECTIONS (REVIEW). ( 31101785 )
2019
49
Diagnosis and Treatment of Chronic Inducible Urticaria. ( 31102545 )
2019
50
Wells syndrome and Chronic Spontaneous Urticaria: report of four cases successfully treated with omalizumab. ( 31106467 )
2019

Variations for Urticaria

ClinVar genetic disease variations for Urticaria:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh37 Chromosome 5, 176831232: 176831232
2 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh38 Chromosome 5, 177404231: 177404231
3 MEFV NM_000243.2(MEFV): c.2084A> G (p.Lys695Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs104895094 GRCh37 Chromosome 16, 3293403: 3293403
4 MEFV NM_000243.2(MEFV): c.2084A> G (p.Lys695Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs104895094 GRCh38 Chromosome 16, 3243403: 3243403

Expression for Urticaria

Search GEO for disease gene expression data for Urticaria.

Pathways for Urticaria

GO Terms for Urticaria

Cellular components related to Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 AOC1 C1S CMA1 CPN1 F12 RNASE3
2 extracellular region GO:0005576 9.28 AOC1 C1S CMA1 CPN1 F12 FCER2

Biological processes related to Urticaria according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.77 C1S F12 IGHE NLRP3 RNASE3
2 Fc-epsilon receptor signaling pathway GO:0038095 9.63 FCER1A IGHE PLCG2
3 positive regulation of receptor internalization GO:0002092 9.51 PLCG2 SELE
4 cellular oxidant detoxification GO:0098869 9.5 LTC4S PTGS1 PTGS2
5 long-chain fatty acid biosynthetic process GO:0042759 9.49 LTC4S PTGS2
6 prostaglandin metabolic process GO:0006693 9.48 PTGS1 PTGS2
7 prostaglandin biosynthetic process GO:0001516 9.43 PTGS1 PTGS2
8 inflammatory response GO:0006954 9.43 ADGRE2 HRH1 NLRP3 PTGS1 PTGS2 SELE
9 peptide metabolic process GO:0006518 9.4 CMA1 CPN1
10 cyclooxygenase pathway GO:0019371 9.26 PTGS1 PTGS2
11 cellular response to histamine GO:0071420 9.16 AOC1 HRH1
12 regulation of inflammatory response GO:0050727 8.92 CMA1 NLRP3 PTGS2 SELE

Molecular functions related to Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.55 ADGRE2 AOC1 C1S F12 TPT1
2 IgE binding GO:0019863 8.96 FCER1A FCER2
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Urticaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....